M&A / Deals Takeda continues to prune partnerships, cuts ties with mRNA-targeting Veritas In Silico pharminent April 15, 2026
Regulatory Lilly’s new obesity pill linked to ‘serious’ safety signals, FDA requests more data pharminent April 15, 2026
M&A / Deals BMS makes a Beeline, bringing 5 assets to biotech’s $300M precision immunology debut pharminent April 15, 2026
Clinical Data S16 Ep52: Medical Crossfire: PD-L1 Inhibition in Advanced Cutaneous Squamous Cell Carcinoma — Mechanistic Rationale and Clinical Application pharminent April 15, 2026
Commercial With nearly a quarter billion in Q1, J&J targets $100B revenue in 2026 pharminent April 14, 2026
Manufacturing Lilly investing billions to prepare for overseas oral GLP-1 launches pharminent April 14, 2026
Regulatory FDA Issues Draft Guidance on Genome Editing Safety Standards to Advance Gene Therapy Development pharminent April 14, 2026
Market Access Mapping the Vertical Integration of Insurers, PBMs, GPOs, Specialty Pharmacies, and Healthcare Services: DCI’s 2026 Update pharminent April 14, 2026
Regulatory MSD, Daiichi Sankyo’s ifinatamab deruxtecan receives FDA priority pharminent April 14, 2026
Other Novo Nordisk and OpenAI forge alliance to drive speedy drug development pharminent April 14, 2026
Regulatory MSD, Daiichi Sankyo’s ifinatamab deruxtecan receives FDA priority pharminent April 14, 2026
Clinical Data Spyre drug for inflammatory bowel disease shows promise in early study pharminent April 13, 2026
Clinical Data Allogene data suggest ‘off-the-shelf’ CAR-T could delay relapse in lymphoma pharminent April 13, 2026
Policy / Pricing FDA Reminds More Than 2,200 Sponsors and Researchers to Disclose Trial Results pharminent April 13, 2026
Manufacturing USP adds Tamiflu, Trulicity to vulnerable list as upstream analysis reshapes supply concerns pharminent April 13, 2026
Clinical Data Allogene stock sails after CAR T clears residual lymphoma in early data cut pharminent April 13, 2026
Other 220: An Interview With Dr. Jaime Moore on Obesity Medications and Neuromuscular Disease pharminent April 13, 2026
Clinical Data Revolution rises 40% as pancreatic cancer drug doubles survival pharminent April 13, 2026
Regulatory IDEAYA and Servier’s eye cancer drug heads to FDA after delivering ‘best in class’ efficacy pharminent April 13, 2026
M&A / Deals AbbVie enters world of pain in up to $715M deal with China’s Haisco pharminent April 13, 2026
Regulatory FDA issues complete response letter to Replimune’s RP1 for melanoma pharminent April 13, 2026
Regulatory FDA issues complete response letter to Replimune’s RP1 for melanoma pharminent April 13, 2026
